Mineralocorticoid receptor (MR) overactivation promotes inflammation and fibrosis, leading to renal dysfunction and muscle loss. Finerenone, a non-steroidal selective MR antagonist, may mitigate these effects. This study aimed to evaluate the impact of finerenone on sarcopenia prevention in chronic kidney disease (CKD) patients by assessing muscle mass and strength. A prospective observational study was conducted, enrolling 21 male patients with CKD stage 3-4. Muscle mass and strength were assessed before and after six months of finerenone treatment using bioimpedance analysis (BIA) and handgrip strength measurement. Biochemical markers, including serum creatinine (Cr), albumin, C-reactive protein (CRP), and proteinuria, were measured. Patients with hyperkalemia or follow-up loss were excluded from the analysis. The mean age of the patients was 65.9 years. There was no significant difference in skeletal muscle mass before and after finerenone treatment (27.5 ± 3.2 kg vs. 27.3 ± 3.1 kg, p = 0.421). Similarly, handgrip strength did not show a significant change (28.6 ± 4.5 kg vs. 28.1 ± 4.3 kg, p = 0.538). Serum albumin (4.1 ± 0.3 g/dL vs. 4.2 ± 0.3 g/dL, p = 0.291), and CRP (1.8 ± 1.2 mg/L vs. 1.7 ± 1.1 mg/L, p = 0.474) also remained unchanged. Logistic regression analysis showed no significant association between finerenone use and improvements in muscle mass or strength (OR 1.02, 95% CI 0.87-1.19, p = 0.72). Although this study did not demonstrate a statistically significant effect of finerenone, several limitations must be considered. The small sample size and short follow-up period may have limited the statistical power to detect meaningful differences. Additionally, sarcopenia progression is influenced by multiple factors which were not fully controlled in this study. Given finerenone's potential anti-inflammatory and renal-protective properties, further large-scale, long-term studies are warranted to elucidate its role in sarcopenia prevention and management.